ArticleEClinicalMedicine2020

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.

Bruno Coudert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.